High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics.

Claudia V KeschLeubet YirgaKatharina DendlAnalena HandkeChristopher DarrUlrich KrafftJan Philipp RadtkeStephan TschirdewahnTibor SzarvasLadan FazliMartin GleaveFrederik L GieselUwe HaberkornBoris Hadaschik

Published in: European journal of nuclear medicine and molecular imaging (2021)

Increased FAP tissue expression supports the use of FAP inhibitor (FAPI)-molecular theranostics in CRPC.

Keyphrases

poor prognosis
single molecule
binding protein
long non coding rna